痛风患者非布司他与别嘌醇心血管风险的时间依赖性:一项单阶段Meta分析
结果显示风险比随时间变化,早期显著降低但随时间衰减,>48个月时无显著差异。
要点
- 非布司他与别嘌醇的心血管风险比在0-12、12-24、24-48个月分别为0.89、0.58、0.86,>48个月为1.09。
- 全因死亡风险比在相同间隔分别为0.70、0.39、0.75、1.02。
- 风险降低主要出现在早期,随时间推移而衰减。
核心结论
- 非布司他与别嘌醇相比的心血管和死亡风险呈时间依赖性,早期显著降低但随时间衰减。
主要发现
- 心血管风险HR:0-12个月0.89(95%CI 0.79-0.99),12-24个月0.58(0.50-0.68),24-48个月0.86(0.74-0.99),>48个月1.09(0.81-1.46)。
- 全因死亡HR:0-12个月0.70(0.62-0.79),12-24个月0.39(0.33-0.45),24-48个月0.75(0.65-0.86),>48个月1.02(0.77-1.34)。
关键数值与推荐
- 预设时间区间为0-12、12-24、24-48、>48个月,采用混合效应Cox模型估计时间变化风险比。
临床怎么用
- 临床管理应关注时间依赖性风险,早期可能获益更明显,长期需持续监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Whether febuxostat is associated with an increased cardiovascular risk compared with allopurinol in patients with gout remains controversial, with major randomized trials reporting conflicting results. This study aims to perform a comprehensive meta-analysis using reconstructed individual participant data (IPD) to evaluate the time-varying cardiovascular and mortality risk of febuxostat vs. allopurinol in gout. METHODS: We conducted a one-stage individual participant data meta-analysis. PubMed, Embase and Cochrane Library were searched up to November 2025 for randomized controlled trials and propensity score-matched observational studies reporting Kaplan-Meier curves for cardiovascular risk or all-cause mortality. Individual patient data were reconstructed from published curves. Time-varying hazard ratios (HRs) were estimated using a mixed-effects Cox model with treatment-by-time interaction across pre-specified intervals (0-12, 12-24, 24-48, >48 months). RESULTS: Four studies (n = 19 090) were included. Analysis revealed significant time-varying effects. For cardiovascular risk, HRs were 0.89 (95% CI 0.79-0.99) at 0-12 months, 0.58 (0.50-0.68) at 12-24 months, 0.86 (0.74-0.99) at 24-48 months and 1.09 (0.81-1.46) after >48 months. For all-cause mortality, HRs were 0.70 (0.62-0.79), 0.39 (0.33-0.45), 0.75 (0.65-0.86) and 1.02 (0.77-1.34) across the same intervals, respectively. CONCLUSION: The cardiovascular and mortality risk of febuxostat relative to allopurinol is time-dependent, showing a significant early reduction that attenuates over time. These findings advocate for a time-aware approach to clinical management and monitoring.
引用
- Wei Q, Shi Y, Hu R, et al. Time-varying cardiovascular risk of febuxostat vs. allopurinol in gout: a one-stage meta-analysis. Rheumatology (Oxford). 2026. PMID: 42629330. doi:10.1093/rheumatology/keag457
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。